Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States.
| Title: | Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States. |
|---|---|
| Authors: | Parthan A; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.; Royston M; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.; Thanataveerat A; Genesis Research Group, Hoboken, New Jersey, USA.; East EL; Genesis Research Group, Hoboken, New Jersey, USA.; Parzynski CS; Genesis Research Group, Hoboken, New Jersey, USA.; Habib AA; University of California, Irvine, California, USA. |
| Source: | Muscle & nerve [Muscle Nerve] 2024 Feb; Vol. 69 (2), pp. 157-165. Date of Electronic Publication: 2023 Nov 29. |
| Publication Type: | Observational Study; Journal Article |
| Language: | English |
| Journal Info: | Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 7803146 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4598 (Electronic) Linking ISSN: 0148639X NLM ISO Abbreviation: Muscle Nerve Subsets: MEDLINE |
| Imprint Name(s): | Publication: : Hoboken, NJ : John Wiley & Sons; Original Publication: New York, NY : John Wiley & Sons |
| MeSH Terms: | Immunoglobulins, Intravenous*/therapeutic use ; Myasthenia Gravis*/drug therapy; United States/epidemiology ; Humans ; Plasma Exchange ; Health Care Costs ; Immunosuppressive Agents ; Cost of Illness |
| Abstract: | Introduction/aims: If myasthenia gravis (MG) symptoms are inadequately controlled, patients may experience exacerbations or life-threatening myasthenic crises. Patients with inadequately controlled MG symptoms tend to be treated with chronic intravenous immunoglobulin (IVIg) therapy and/or multiple immunosuppressant therapies (ISTs). This study aimed to examine disease burden, healthcare resource utilization, and associated costs in these patients.; Methods: This was a retrospective observational study using a claims database. Patients with MG were classified into three cohorts based on treatment over a 1-y follow-up period: (a) treated with four or more IVIg episodes (chronic IVIg cohort); (b) received two or more non-steroidal ISTs (NSISTs) sequentially (multiple NSIST cohort); (c) received neither chronic IVIg nor multiple NSISTs (reference cohort). Incidences of crises and exacerbations and annual healthcare costs in each cohort were estimated.; Results: In total, 3516 patients with MG were included in the analysis. Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p |
| References: | Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry. 1998;65(4):492-496.; Nair AG, Patil-Chhablani P, Venkatramani DV, Gandhi RA. Ocular myasthenia gravis: a review. Indian J Ophthalmol. 2014;62(10):985-991.; Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.; Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141-149.; Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. 2018;58(1):99-105.; Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419-425.; Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.; Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114-122.; Boscoe AN, Xin H, L'Italien GJ, Harris AL, Cutter GR. Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis. 2019;20(4):173-181.; Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal analysis of disease burden in refractory and nonrefractory generalized myasthenia gravis in the United States. J Clin Neuromuscul Dis. 2020;22(1):11-21.; Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America patient registry sample. J Clin Neurol. 2019;15(3):376-385.; R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2016.; Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14-24.; Guptill JT, Marano A, Krueger A, Sanders DB. Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve. 2011;44(6):907-911.; Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13(2):85-94.; Desai R, Abbas SA, Fong HK, et al. Burden and impact of takotsubo syndrome in myasthenic crisis: a national inpatient perspective on the under-recognized but potentially fatal association. Int J Cardiol. 2020;299:63-66.; Liu C, Li T, Wang Q, Xu A, Wu B. Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychol Health Med. 2021;26(2):221-227.; Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22(7):1164-1169.; Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America registry analysis. Muscle Nerve. 2019;60(6):700-706.; Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient's perspective. J Neurol. 2021;269:3050-3063.; Schepelmann K, Winter Y, Spottke AE, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(1):15-23.; Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986. |
| Grant Information: | Alexion, AstraZeneca Rare Disease |
| Contributed Indexing: | Keywords: IVIg; autoimmune disease; exacerbation; healthcare resource; myasthenia gravis; myasthenic crisis |
| Substance Nomenclature: | 0 (Immunoglobulins, Intravenous); 0 (Immunosuppressive Agents) |
| Entry Date(s): | Date Created: 20231129 Date Completed: 20240118 Latest Revision: 20240118 |
| Update Code: | 20260130 |
| DOI: | 10.1002/mus.27992 |
| PMID: | 38018505 |
| Database: | MEDLINE |
Observational Study; Journal Article